Novo Nordisk cuts 2025 forecast again, cites slower sales of Wegovy and Ozempic (NVO:NYSE)

Novo Nordisk A/S (NVO) trimmed its forecast for a fourth time this year on Wednesday, citing lower-than-expected sales of its blockbuster drugs Wegovy and Ozempic. This year's sales will rise only as much as 11%, while operating profit expands by 7% at most ...